Cisplatin: Process and future

Journal of B.U.ON.

Volumn 18, Issue 3, 2013, Pages 564-569

  Stathopoulos, George P ^a  

^a Errikos Dunant Hospital   (Greece)

Author keywords

Cisplatin; Lipoplatin; Lung adenocarcinoma; Non small cell lung cancer; Novel formulation; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LIPOPLATIN; NANOCARRIER; NAVELBINE; PACLITAXEL; PEMETREXED; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ASTHENIA; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; LEUKOPENIA; LIPOSOMAL DELIVERY; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; NAUSEA; NEPHROTOXICITY; OVERALL SURVIVAL; PANCREAS CANCER; REVIEW; STOMACH CANCER; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS;

EID: 84885692279     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Lince L, Lulu DJ. Carcinoma of the lung. A comparative series of 687 cases. Arch Surg 1971; 102:103-107.
2. Host H. Cyclophosphamide (NSC-26271) as adjuvant to radiotherapy in the treatment of unresectable bronchogenic carcinoma. Cancer Chemother Rep 1973; 4:161-164.
3. Cotes FP, Takita H, Holland JF. Adriamycin in advanced bronchogenic carcinoma. Cancer 1973; 34:161-164.
4. Hoeltgen TM, McIntyre JM, Perlia CP et al. Adriamycin and cytoxan in the treatment of inoperable lung cancer. Cancer 1983; 51: 2005-2012. (Pubitemid 13092448)
5. Casper ES, Gralla RI, Kelsen DP et al. Phase II study of high-dose cis-dichlorodiammineplatinum(II) in the treatment of non-small cell lung cancer. Cancer Treat Rep 1979; 63: 2107-2109. (Pubitemid 10138998)
6. Gralla RJ, Casper ES, Kelson DP et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 1981; 95: 414-420. (Pubitemid 11007366)
7. Ruckdeschel JC, Finkelstein DM, Mason DA, Creech RH. Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V - a randomized comparison of four cisplatin-containing regimens. J Clin Oncol 1985; 3: 72-79. (Pubitemid 15187700)
8. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 899-909.
9. Weiden PL, Piantadosi S. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Group. J Natl Cancer Inst 1991; 83: 266-273.
10. Burkes RL, Ginsberg RL, Shepherd FA et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial. J Clin Oncol 1992; 10: 580-586.
11. Rousell R, Gümez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330: 153-158. (Pubitemid 24026882)
12. Dillman RO, Seagren SL, Propert KJ et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323: 940-945. (Pubitemid 20332333)
13. Green MR. Chemotherapy and radiation for stage III non-small cell lung cancer. Educational book ASCO 1994, pp 178-182.
14. Le Chevalier T, Brisgand D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-367.
15. Lynch TJ. Treatment of stage III non-small cell lung cancer. Educational book ASCO 1998, pp 265-275.
16. Crino L, Scagliotti GV, Ricci S et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17: 3522-3530. (Pubitemid 29517923)
17. Frasci G, Panza N, Comella P et al. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group. J Clin Oncol 1999; 17: 2316-2325. (Pubitemid 29368229)
18. Comella P, Frasci G, Panza N et al. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group. J Clin Oncol 1999; 17: 1526-1534. (Pubitemid 29220861)
19. Bonomi P, Kim KM, Fairclough D et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18: 623-631. (Pubitemid 30078543)
20. Greco FA, Hainsworth JD. Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II trial. Semin Oncol 1997; 24 (4 Suppl 12): S12-14, S12-17.
21. Belani CP, Keams CM, Zuhowski EG et al. Phase I trial, including pharmacokinetic and pharmacodynamic correlations of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 1999; 17: 676-684. (Pubitemid 29075257)
22. 2) plus carboplatin in non-small cell lung cancer: a randomized study. Semin Oncol 1997; 24 (Suppl 12): S12-30-S12-33.
23. Pectasides D, Aspropotamitis A, Halikia A et al. Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1999; 17: 3816-3821.
24. Stathopoulos GP, Veslemes M, Georgatou N et al. Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. Ann Oncol 2004; 15: 1048-1055. (Pubitemid 39089781)
25. Georgoulias V, Kouroussis CH, Androulakis N et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol 1999; 17: 914-920. (Pubitemid 29109323)
26. Giaccone G. Twenty-five years of treating advanced NSCLC: what have we achieved? Ann Oncol 2004; 15 (Suppl 4): iv81-83. (Pubitemid 39585316)
27. Ponn RB, Lo Cicero J III, Daly BOT. Surgical treatment of non-small cell lung cancer. In: Shields TW, Lo Cicero III J, Ponn R et al. (Eds): General Thoracic Surgery (6th Edn). Philadelphia PA, Lippincott Williams and Wilkins, 2005, pp 1548-1587.
28. Ferlay J, Bray F, Pisani P et al. Globocam 2000 Cancer Incidence. Mortality and Prevalence Worldwide. Version 1.0 Lyon, France (ARC Press 2001).
29. PORT Meta-analysis Trialists Group. Portoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998; 352: 257-263.
30. Chang AY, DeVore R, Johnson D. Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small-cell lung cancer. Semin Oncol 1996; 23 (2 Suppl 5): 19-21. (Pubitemid 26130110)
31. Akerley W, Choy H, Safran H et al. Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Semin Oncol 1997; 24 (4 Suppl 12): S12-10, S12-13.
32. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354-2362. (Pubitemid 30415821)
33. Miller VA, Krug LM, Ng KK et al. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18: 1346-1350. (Pubitemid 30159855)
34. Fossella FV, Lee JS, Derille J et al. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer. Semin Oncol 1995; 22(2 Suppl 4): 22-29.
35. Gandara DR, Vokes E, Green M et al. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 2000; 18: 131-135. (Pubitemid 30036346)
36. Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res 2005; 25: 3031-3039.
37. Boulikas T, Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 2004; 12:3-12.
38. Devarajan P, Tarabishi R, Mishra J et al. Low renal toxicity of lipoplatin compared to cisplatin in animals. Anticancer Res 2004; 24: 2193-2200. (Pubitemid 39166294)
39. Stathopoulos GP, Boulikas T, Vougiouka M et al. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (lipoplatin): phase I study. Oncol Rep 2005; 13: 589-595.
40. Stathopoulos GP, Boulikas T. Lipoplatin formulation review article. J Drug Deliv 2012; 10: 2012/ 581363.
41. Stoeck A, Gast D, Sanderson MP et al. L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol Oncol 2007; 104: 461-469. (Pubitemid 46156956)
42. Stathopoulos GP, Boulikas T, Vougiouka M et al. Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. Oncol Rep 2006; 15: 1201-1204.
43. Koukourakis MI, Giatromanolaki A, Pitakoudis M et al. Concurrent liposomal cisplatin (lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I-II study. Int J Radiat Oncol Biol Phys 2009; 78: 150-155.
44. Farhat FS, Ibrahim K, Kattan J et al. Preliminary results of phase II study of liposomal cisplatin. Vinorelbine combination as first-line treatment in HER-2/neu negative metastatic breast cancer (MBC). Proceedings of the ASCO Annual Meeting 2009, 2068 (abstr).
45. Mylonakis N, Athanassiou A, Ziras N et al. Phase II study of liposomal cisplatin (lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer 2010; 68: 240-247.
46. Stathopoulos GP, Antoniou D, Dimitroulis J et al. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Ann Oncol 2010; 21: 2227-2232.
47. Stathopoulos GP, Antoniou D, Dimitroulis J et al. Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. Cancer Chemother Pharmacol 10.1007/s0080-011, 2011; 1572-1575.
48. Peters S, Adjei AA, Gridelli C et al. Metastatic non-small-cell lung cancer (NSCLC). ESMO Clinical Practice Guidelines for Diagnosis and Follow-up. Ann Oncol 2012; 23 (Suppl 7): vii 56-vii 64.
49. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132. (Pubitemid 41058344)
50. Pao W, Miller VA, Politi KA et al. Acquired resistance of drug adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2:e73.
51. Englman JA, Chen L, Tan Y et al. Effective use of P13K and MEK inhibitors to treat mutant k-ras and P13K CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-1356.
52. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042-2048.
53. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-687.
54. Parlati F, Lee KB, Lindsten K et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009; 114: 3439-3444.